16 results about "Bovine milk" patented technology

This invention relates to the field of emulsion technology, specifically disclosing a method for preparing a casein micelle-phenol-whey protein ternary complex, comprising: S1, screening bovine milk with κ-casein genotype AA, and using it as raw material to prepare a casein micelle solution; S2, adding a phenolic compound to the casein micelle solution to form a casein micelle-phenol binary complex mixed solution; S3, dialyzing the mixed solution obtained in step S2; S4, adding whey protein; by combining a phenolic compound (such as EGCG) with casein micelles and whey protein to form a ternary complex, the degree to which proteins form dense clots in the stomach can be reduced, making the clot structure looser, thereby accelerating the digestion rate and reducing stomach discomfort.

The invention belongs to the technical field of biology, and discloses a molecular marker for detecting the character of fatty acid in cow milk and an identification method. The molecular marker SNP provided by the invention is g.16772853G / T, and is related to the contents of fatty acids C14: 0, C14: 1, C16: 1, C17: 0 and C18: 0 of cow milk. By utilizing the SNP provided by the invention, early screening can be realized in the dairy cow breeding process, the breeding cost can be reduced, and the fatty acid content of milk can be effectively increased or reduced according to production requirements. The method is high in detection accuracy and low in cost, and has an important application prospect in dairy cow breeding.

The invention relates to the technical field of mRNA vaccine preparation, and particularly discloses a porcine epidemic diarrhea virus mRNA vaccine and a preparation method thereof. The mRNA vaccine is prepared by adopting cow milk source exosome as a carrier and wrapping mRNA encoding PEDV-S protein in the carrier through an ultrasonic loading method. According to the preparation method, the encapsulation efficiency of mRNA and the stability of the vaccine are remarkably improved, the prepared vaccine can more efficiently promote antigen expression, stronger cellular immunity and humoral immunity are induced in a mouse body, and a safe and efficient novel vaccine candidate is provided for preventing and controlling porcine epidemic diarrhea.

This invention relates to an endogenous antimicrobial peptide from bovine milk and its applications. The antimicrobial polypeptide compound VAVALARPKHPIK is derived from endogenously enzymatically hydrolyzed bovine casein, with the amino acid sequence Val-Ala-Val-Ala-Leu-Ala-Arg-Pro-Lys-His-Pro-Ile-Lys. It exhibits broad inhibitory activity against both Gram-positive and Gram-negative bacteria, including *Porphyromonas gingivalis*, *Escherichia coli*, and *Staphylococcus aureus*. This antimicrobial peptide shows promising applications as a health supplement and / or medical device or pharmaceutical for the prevention and / or reduction of infectious diseases, as a food antimicrobial agent, in novel functional foods, pet food and animal feed additives, and in daily chemical products.

Milk quality can be compromised by physiological conditions affecting dairy mammals, notably mastitis. Mastitis is an inflammatory disease of the mammary gland that may pose significant health and economic challenges. To address this, a system is proposed for monitoring at least one mammal to predict the onset of a clinical condition, such as, for example, mastitis. The system may be configured to sense one or more characteristics descriptive of mammal-related information, receive sensor data corresponding to those characteristics, and process the data to forecast the onset of mastitis within an upcoming time interval. Early detection enables timely intervention, promoting animal welfare and preserving milk quality.

The application provides a method for separating alpha s Casein, and belongs to the technical field of protein separation. The method takes bovine milk casein as raw material, separates a first precipitate mainly containing calcium-sensitive casein through low-temperature continuous phase change, and then redissolves the first precipitate, controls the feed liquid ratio during redissolution and the standing time in a low-temperature alkaline environment, maximally dissolves beta-casein, and thus obtains a precipitate rich in alpha s Casein. The method has high purity and yield of alpha s Casein, and the purity and yield of alpha Casein are 69.17%-88.93% and 81.96%-91.15% respectively.

The invention relates to a fat composition and a nutritional composition comprising such fat composition. The nutritional composition is particularly suitable for therapeutic applications in treating gut discomfort and / or constipation as well as in non-therapeutic applications for reducing the intestinal formation of calcium and magnesium fatty acid soaps. The fat composition comprises a mixture of triacylglycerols (TAG) originating from a bovine milk fat source and a vegetable lipid source, said mixture being characterized by: (a) a content of butanoate groups (C4:0) of 0.5-2.8% by weight based on total weight of fatty acid acyl groups in TAG; (b) a wLCSFA(sn-1,3) of 18.0-35.0% by weight; (c) a mLCFA (sn-1,3) of 48.0-61.0 mol %; and (d) a ratio mLCFA (sn-1,3) / SFA of 0.70-1.25, wherein: —LCFA(sn-1,3) are the long chain fatty acid acyl groups having a chain length of 12 or more carbon atoms at the sn-1 and sn-3 position in TAG; —LCSFA(sn-1,3) are the long chain saturated fatty acid acyl groups having a chain length of 12 or more carbon atoms at the sn-1 and sn-3 position in TAG; —wLCSFA(sn-1,3) is the amount of LCFA(sn-1,3) in % by weight based on total weight of fatty acid acyl groups in TAG; —mLCFA(sn-1,3) is the mole fraction of LCFA(sn-1,3) based on total moles of fatty acid acyl groups in the TAG as expressed in mol %; and—SFA is the mole fraction of saturated fatty acid acyl groups in the TAG as expressed in mol %.

This invention relates to the field of nutritional food technology, specifically disclosing a nutritional composition for regulating sleep, its preparation method, and its application. The nutritional composition comprises bovine milk exosomes, 1,3-dioleoyl-2-palmitoylglycerol, and 1-oleoyl-2-palmitoyl-3-linoleic acid triglyceride. The nutritional composition provided by this invention can promote the expression levels of γ-aminobutyric acid receptors and melatonin, thereby improving sleep, assisting in the regulation of circadian rhythms, and increasing the proportion of deep sleep. This invention provides a new approach for preparing nutritional foods that regulate sleep.

This application relates to the field of dairy processing technology, specifically disclosing a composite DHA milk protein peptide, its preparation method, and its application. The process involves homogenizing DHA algal oil with an emulsifier under high pressure to prepare a nano-sized DHA emulsion (particle size 100-300 nm), achieving efficient encapsulation and stabilization protection of DHA. The resulting DHA emulsion is then mixed with skim milk, and targeted enzymatic hydrolysis with trypsin and flavor protease at 45-55℃ and pH 6.5-7.0 for 2-4 hours hydrolyzes the milk protein into small molecule peptides. After enzyme inactivation and drying, the composite DHA milk protein peptide is obtained. This process significantly improves protein digestibility while protecting DHA stability; in vitro simulated digestion experiments show a digestibility and absorption rate of over 94.8%. Further application of this protein peptide in the preparation of liquid milk yields a DHA retention rate of over 92%, and even after 6 months of storage at room temperature, there is no obvious oxidized fishy odor. This effectively solves the technical problems of DHA's easy oxidation and poor stability in dairy products, demonstrating good nutritional synergistic value and promising industrial application prospects.

The invention provides hypoallergenic eye-protecting children milk tablets and a preparation method thereof, and the hypoallergenic eye-protecting children milk tablets comprise hypoallergenic formula whey protein powder, casein hydrolysate freeze-dried powder, eye-protecting composite active ingredients, a flavoring agent, an antioxidant and auxiliary materials, wherein the low-sensitization formula whey protein powder comprises a mixture of lactoferrin powder, alpha-lactalbumin powder and low-sensitization beta-LG protein powder, and the low-sensitization beta-LG protein powder comprises a non-covalent compound formed by combining a small molecule substance and cow milk beta-LG; the casein hydrolysate freeze-dried powder comprises bovine milk casein hydrolyzed by Alcalase protease and bacillus licheniformis protease. The selected small molecule substances are all dairy product available additives permitted by GB2760-2024 National Food Safety Standard Food Additives Usage Standards, and related reports of the food additives for beta-LG sensitization improvement do not exist in the existing research at present, so that the blank in the prior art is filled, and the eating safety of children is guaranteed.

The invention discloses a process for extracting high-purity lactoferrin and lactoperoxidase from fresh milk, which comprises the following steps: centrifugally degreasing the fresh milk to obtain skimmed milk; sterilizing and concentrating the obtained skimmed milk through a ceramic membrane to obtain sterilized concentrated milk liquid; adsorbing and eluting the sterilized concentrated milk liquid through cation exchange resin, and collecting eluent rich in lactoferrin and lactoperoxidase; desalting and concentrating the obtained eluent through a ceramic membrane to obtain secondary concentrated milk liquid; the obtained secondary concentrated milk liquid is introduced into a simulated moving bed chromatography system, a lactoferrin extracting solution is obtained from an extracting solution outlet of the simulated moving bed chromatography system, and a lactoperoxidase extracting solution is obtained from a raffinate outlet; carrying out desalination and concentration by using an ultrafiltration membrane, and carrying out spray drying to obtain a lactoferrin final product and a lactoperoxidase final product; the purity of lactoferrin in the obtained lactoferrin final product is 95% or above, and the purity of emulsified peroxidase in the obtained lactoperoxidase final product is 90% or above.

The present application relates to a kind of bovine milk endogenous antibacterial peptide and its application, it is from endogenous enzyme hydrolysis casein of antibacterial polypeptide compound PKTKVIPYVRYL of milk, its amino acid sequence is Pro-Lys-Thr-Lys-Val-Ile-Pro-Tyr-Val-Arg-Tyr-Leu.Gram-positive bacteria and gram-negative bacteria have extensive inhibitory activity respectively, including gingival porphyromonas, escherichia coli, staphylococcus aureus etc..The antibacterial peptide can be used as the health care product and / or medical equipment or drug, food bacteriostatic agent, new functional food, pet food and animal feed additive and daily chemical in preventing and / or reducing infection disease, with good application prospect.

The application discloses a DR5TP polypeptide targeted glycoengineering milk exosome gene delivery system and anti-tumor application thereof, and particularly relates to a glycoengineering milk exosome (mExo) targeted siPDL1 gene silencing drug delivery system and a method for preparing the system (mExo@siPDL1-DR5TP) and anti-tumor application thereof. The system is prepared by enzyme-mediated glycosylation engineering and bio-orthogonal coupling technology, and DR5 ligand mimetic peptide DR5TP is specifically modified on the surface of the exosome, and siPDL1 is efficiently loaded, so that targeted treatment of DR5 overexpressing tumor cells is realized.

The application belongs to the technical field of dairy product processing. A method for utilizing endogenous lipase in cow milk and application of the method in preparation of zero-fat pasteurized milk are disclosed. Through the process of defatting, membrane breaking and endogenous enzyme control time enzymolysis, the activity of endogenous lipase is fully activated without adding exogenous enzymes and essence, so as to significantly improve the milk aroma, fruit aroma and sweetness of the product, while inhibiting the generation of fishy smell, realizing the unity of natural flavor enhancement and clean label, and being suitable for flavor improvement of zero-fat dairy products.

The application provides a milk protein source urokinase-type plasminogen activator inhibitory peptide and application thereof. Through a combination of virtual screening by molecular docking and in-vitro experiment verification, two u-PA inhibitory activity polypeptides PEVMGVSK and HIQKEDVPSE derived from bovine milk casein are obtained. The two polypeptides can be stably combined with the u-PA active site through multiple intermolecular forces, have a significant inhibitory effect on u-PA-mediated plasminogen activation, can effectively improve the storage period stability of ultra-high temperature instant sterilized milk, delay protein hydrolysis and aging gel formation, and can inhibit the plasmin clot lysis and MDA-MB-231 human breast cancer cell migration in a concentration-dependent manner. The polypeptides obtained by the application have application potential and practical value in the fields of dairy product quality improvement, hemostatic drugs and anti-cancer drug research, etc. as natural source active ingredients.

The invention belongs to the technical field of biological medicines, and relates to a nano-motor hybrid cow milk extracellular vesicle delivery system as well as a preparation method and application thereof. The delivery system comprises 18: 0 LPA and nano-motor hybridized cow's milk extracellular vesicles loaded with the 18: 0 LPA. The method comprises the following steps: mixing cow milk extracellular vesicles with 18: 0 LPA, and carrying out low-temperature ultrasonic treatment to complete loading; the preparation method comprises the following steps: dissolving MPC in PBS, adding a cross-linking agent mixture, then adding APS and TEMED for in-situ polymerization, fully dialyzing in PBS, re-dispersing, and keeping at 4 DEG C for 1 h; adding mEVs-LPA for mixing, and then adding n-L-arginine for reacting for 2 hours to obtain a product. The cow's milk extracellular vesicle delivery system based on nano motor driving is constructed, precise targeted delivery of 18: 0 LPA can be achieved, and precise targeted therapy of a focus part is achieved while the bioavailability of 18: 0 LPA is improved.